Janet Soul, MD is a pediatric neurologist whose area of clinical expertise and research is in Fetal and Neonatal Neurology with a focus on the etiology, pathogenesis, outcome and prevention of early acquired brain injury. Dr. Soul directs the Fetal-Neonatal Neurology Program that provides specialized care to fetuses, newborns and children with neurologic disorders that begin in utero or in the neonatal period. This program, with its associated clinical services, provides specialized training for neurology, neonatology and pediatric fellows and residents.
Dr. Soul’s research and writing are focused on early acquired brain injury, particularly hypoxic-ischemic brain injury, involving a lack of oxygen and blood flow to the brain; the treatment of seizures in term newborns; and periventricular leukomalacia (injury to the white matter of the brain), intraventricular hemorrhage (bleeding into the ventricles of the brain), and hydrocephalus in preterm newborns. Dr. Soul is the PI for a randomized, double-blind, controlled trial of bumetanide for the treatment of neonatal seizures, funded by an R01 from NINDS (NS066929), which is the first to study a novel drug (bumetanide) with an anticonvulsant mechanism specific to the newborn brain. The broad goal of her research is to understand the causes of these brain injuries and to detect them at their earliest onset in order to develop and test neuroprotective therapies that prevent or minimize brain injury.